# US 2015/0148307 A1 · Methods and compositions for the prognosis and treatment of relapsed leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148307 A1
- Document ID: US20150148307A1
- Status: Published application
- Kind: A1
- Application number: 14/399,467
- Filed: 2013-05-07
- Published: 2015-05-28
- Earliest claimed: 2012-05-07
- Assignees: New York University
- Inventors: William L. Carroll; Julia A. Meyer
- Web page: https://patentgrep.com/patent/US20150148307A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/52: Purines, e.g. adenine
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on the determined prognosis of the subject.

## Claims

### Claim 1

A method of determining a subject's risk of developing relapse leukemia, said method comprising:
providing an isolated biological sample from a subject having leukemia;
contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in one or more genes selected from the group consisting of NT5C2, RGS12, LPHN1, CAND1, PRMT2,NIPSNAP1, USP7, TULP4, CBX3, COBRA1, SDF2, FBXO3, SCARF1, NEGR1, DPH5, SMEK2, MIER3, DOPEY1, ZNF192, EVI2A, GSPT2, and MYC;
detecting the presence or absence of the one or more mutations in the one or more genes based on said contacting; and
determining the subject's prognosis based on said detecting, wherein the presence of the one or more mutations in the one or more said genes predicts an increased likelihood the subject will develop relapse leukemia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample comprises a bone-marrow or peripheral blood sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has acute lymphoblastic leukemia.

### Claim at position 4

4-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the one or more mutations is in NT5C2 and encodes an amino acid substitution at one or more amino acid residues corresponding to amino acid positions 238, 367, 408, and/or 445 of SEQ ID NO: 2

### Claim at position 6

9-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the one or more mutations in NT5C2 encode an amino acid insertion at an amino acid position corresponding to position K404 of SEQ ID NO: 2.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the one or more mutations is in RGS12 and encodes an alanine to valine substitution at an amino acid position corresponding to A53 of SEQ ID NO: 4.

### Claim 16 (depends on 1)

The method of claim 1, wherein the one or more mutations is in LPHN1 and encodes a glutamic acid to glutamine substitution at an amino acid position corresponding E274 of SEQ ID NO: 6.

### Claim 17 (depends on 1)

The method of claim 1, wherein the one or more mutations is in CAND1 and encodes a leucine to phenylalanine substitution at an amino acid position corresponding to L626 of SEQ ID NO: 8.

### Claim 18 (depends on 1)

The method of claim 1, wherein the one or more mutations is in PRMT2 and encodes a methionine to leucine substitution at an amino acid position corresponding to M244 of SEQ ID NO: 10.

### Claim 19 (depends on 1)

The method of claim 1, wherein the one or more mutations is in NIPSNAP1 and encodes a serine to isoleucine substitution at an amino acid position corresponding S171 of SEQ ID NO: 12.

### Claim 20 (depends on 1)

The method of claim 1, wherein the one or more mutations is in USP7 and encodes a threonine to serine substitution at an amino acid position corresponding to T730 of SEQ ID NO: 14.

### Claim 21 (depends on 1)

The method of claim 1, wherein the one or more mutations is in TULP4 and encodes a leucine to arginine substitution at an amino acid position corresponding to L1341 of SEQ ID NO: 16.

### Claim 22 (depends on 1)

The method of claim 1, wherein the one or more mutations is in CBX3 and encodes a cysteine to tyrosine substitution at an amino acid position corresponding to C69 of SEQ ID NO: 18.

### Claim 23 (depends on 1)

The method of claim 1, wherein the one or more mutations is in COBRA1 and encodes a methionine to isoleucine substitution at an amino acid position corresponding to M106 of SEQ ID NO: 20.

### Claim 24 (depends on 1)

The method of claim 1, wherein the one or more mutations is in SDF2 and encodes an arginine to glutamine substitution at an amino acid position corresponding to R73 of SEQ ID NO: 22.

### Claim 25 (depends on 1)

The method of claim 1, wherein the one or more mutations is in FBXO3 and encodes a valine to glutamic acid substitution at an amino acid position corresponding to V414 of SEQ ID NO: 24.

### Claim 26 (depends on 1)

The method of claim 1, wherein the one or more mutations comprises a missense mutation in SCARF1 that encodes a cysteine residue instead of a stop codon after the amino acid position corresponding to R337 of SEQ ID NO: 26.

### Claim 27 (depends on 1)

The method of claim 1, wherein the one or more mutations is in NEGR1 and encodes a proline to leucine substitution at an amino acid position corresponding to P237 of SEQ ID NO: 28.

### Claim 28 (depends on 1)

The method of claim 1, wherein the one or more mutations is in DPH5 and encodes a serine to phenylalanine substitution at an amino acid position corresponding to S171 of SEQ ID NO: 30.

### Claim 29 (depends on 1)

The method of claim 1, wherein the one or more mutations is in SMEK2 and encodes an arginine to glutamine substitution at an amino acid position corresponding to R543 of SEQ ID NO: 32.

### Claim 30 (depends on 1)

The method of claim 1, wherein the one or more mutations is in MIER3 and encodes a glutamic acid to lysine substitution at an amino acid position corresponding to E266 of SEQ ID NO: 34.

### Claim 31 (depends on 1)

The method of claim 1, wherein the one or more mutations is in DOPEY1 and encodes an arginine to histidine substitution at an amino acid position corresponding to R1864 of SEQ ID NO: 36.

### Claim 32 (depends on 1)

The method of claim 1, wherein the one or more mutations is in ZNF192 and encodes an arginine to proline substitution at an amino acid position corresponding to R473 of SEQ ID NO: 38.

### Claim 33 (depends on 1)

The method of claim 1, wherein the one or more mutations is in EVI2A and encodes an alanine to valine substitution at an amino acid position corresponding to A127 of SEQ ID NO: 40.

### Claim 34 (depends on 1)

The method of claim 1, wherein the one or more mutations is in GSPT2 and encodes a serine to cysteine substitution at an amino acid position corresponding to S559 of SEQ ID NO: 42.

### Claim 35 (depends on 1)

The method of claim 1, wherein the one or more mutations is in MYC and encodes a threonine to histidine substitution at an amino acid position corresponding to T58 of SEQ ID NO: 44.

### Claim 36 (depends on 1)

The method of claim 1, wherein said detecting comprises:
sequencing at least a portion of a nucleotide sequence of the one or more genes comprising the one or more mutations.

### Claim 37 (depends on 1)

The method of claim 1, wherein said detecting comprises:
detecting, in a hybridization assay, hybridization of one or more oligonucleotide probes comprising a nucleotide sequence that is complementary to a nucleotide sequence of a nucleic acid molecule in the sample comprising one or more mutations in the one or more genes.

### Claim 38 (depends on 1)

The method of claim 1, wherein said detecting comprises:
detecting, in an amplification-based assay, amplification of a nucleic acid molecule in the sample comprising the one or more mutations in the one or more genes.

### Claim 39 (depends on 1)

The method of claim 1 further comprising:
administering a therapy suitable for relapse leukemia to the subject when said determining predicts an increased likelihood that the subject will develop relapse leukemia.

### Claim 40

(canceled)

### Claim 41

A method of treating a subject having leukemia comprising:
selecting a subject having leukemia and one or more mutations in one or more genes selected from the group consisting of NT5C2, RGS12, LPHN1, CAND1, PRMT2, NIPSNAP1, USP7, TULP4, CBX3, COBRA1, SDF2, FBXO3, SCARF1, NEGR1, DPH5, SMEK2, MIER3, DOPEY1, ZNF192, EVI2A, GSPT2, and MYC and
administering a therapy suitable for treating relapse leukemia to the selected subject.

### Claim 42 (depends on 41)

The method of claim 41, wherein the therapy suitable for treating relapse leukemia comprises a bone-marrow transplant.

### Claim 43 (depends on 41)

The method of claim 41, wherein the one or more mutations is in NT5C2 and encodes an amino acid substitution at one or more amino acid residues corresponding to amino acid positions 238, 367, 408, and/or 445 of SEQ ID NO: 2

### Claim at position 38

44-47. (canceled)

### Claim 48 (depends on 41)

The method of claim 41, wherein the one or more mutations in NT5C2 encode an amino acid insertion at an amino acid position corresponding to position K404 of SEQ ID NO: 2.

### Claim 49

(canceled)

### Claim 50

A method of preventing or treating relapsed leukemia in a subject comprising:
selecting a subject having one or more NT5C2 gene mutations and
administering to the selected subject an agent that inhibits NT5C2 gene expression and/or NT5C2 encoded enzyme activity under conditions effective to prevent or treat the relapsed leukemia in the subject.

### Claim 51 (depends on 50)

The method of claim 50, wherein the agent inhibits mutant NT5C2 gene expression and/or mutant NT5C2 encoded enzyme activity.

### Claim 52 (depends on 50)

The method of claim 50, wherein the mutation in NT5C2 encodes an amino acid substitution at one or more amino acid residues corresponding to amino acid positions 238, 367, 408, and/or 445 of SEQ ID NO: 2

### Claim at position 44

53-56. (canceled)

### Claim 57 (depends on 50)

The method of claim 50, wherein the NT5C2 gene mutation encodes an amino acid insertion at an amino acid position corresponding to position 404 of SEQ ID NO:2.

### Claim 58

(canceled)

### Claim 59 (depends on 50)

The method of claim 50, further comprising
administering to the selected subject one or more anti-leukemia therapies in conjunction with said agent that inhibits NT5C2 gene expression and/or NT5C2 encoded enzyme activity.

### Claim 60 (depends on 50)

The method of claim 50, wherein the selected subject has acute lymphoblastic leukemia.

### Claim at position 49

61-63. (canceled)

### Claim 64 (depends on 50)

The method of claim 50, wherein the agent comprises a ribonucleoside 5′-monophosphate analogue.
